Gallbladder and Bile Duct Cancer

Start here

Gallbladder and bile duct cancer at a glance

These cancers are uncommon. Where the cancer starts helps determine its symptoms and treatment. Start with the overview below, then read the sections that apply to your diagnosis; you do not need to understand every treatment at once.

• Gallbladder cancer begins in the pear-shaped sac beneath the liver that stores bile.
• Bile duct cancer is called cholangiocarcinoma. It may arise inside the liver, at the liver hilum (where the main bile ducts leave the liver), or farther down the common bile duct.
• Most are adenocarcinomas: cancers that start in gland-forming cells. A specialist examines the tissue to confirm the type, because less common types need different treatment.
• Early cancers may be curable with surgery. Many are found late because small tumours may cause few symptoms.
• A blocked bile duct can cause jaundice and infection. Drainage may be needed before or during cancer treatment.
• For advanced cancer, chemotherapy combined with immunotherapy is a common first treatment. Immunotherapy helps the immune system fight cancer. Tests for changes in the cancer’s genes or proteins, called molecular profiling, may identify a targeted medicine.

The four questions that organise care

Understand

The gallbladder and biliary tree

The liver makes bile. The gallbladder stores it. A branching system of ducts carries it into the small intestine to help digest fats.

Four main cancer sites

“Biliary tract cancer” is a general name for cancers of the gallbladder and bile ducts. Their treatment can differ depending on where they start.

Symptoms and warning signs

Symptoms depend on the site. A tumour inside the liver may cause vague discomfort, while a tumour in a major duct may block bile early.

Symptoms are not a diagnosis

Gallstones, inflammation of the liver or pancreas, bile duct narrowing and infections can cause similar problems. Persistent or unexplained symptoms need assessment, but most people with these symptoms do not have cancer.

Useful details to share with your team

Risk factors

Usually there is no single answer. Risk factors increase probability; they do not prove what caused one person’s cancer, and most people with a risk factor never develop it.

Gallbladder cancer risk factors

• Long-standing gallstones and chronic gallbladder inflammation
• Gallbladder polyps (growths on the lining), especially larger or growing ones, and calcium build-up in the gallbladder wall (porcelain gallbladder)
• An unusual connection between the pancreatic and bile ducts, or bile ducts that are abnormally widened from birth (choledochal cysts)
• Increasing age, obesity and, in some regions, carrying Salmonella bacteria long term

Bile duct cancer risk factors

• Primary sclerosing cholangitis (a condition that scars and narrows bile ducts), choledochal cysts, and repeated bile duct stones or inflammation
• Cirrhosis (long-term liver scarring), chronic hepatitis B or C, and some conditions affecting how the liver processes nutrients
• Infection with liver flukes (parasitic worms) in parts of Asia where they are common
• Inflammatory bowel disease—mainly through its link with primary sclerosing cholangitis
• Smoking, excess alcohol and metabolic risk may contribute, especially for intrahepatic disease

Ask whether relatives need any action; for most families, they do not need special screening.

Jaundice and cholangitis: act early

A blocked bile duct can cause a yellow pigment called bilirubin to build up, causing jaundice. Infection in the bile ducts is called cholangitis and can become life-threatening quickly.

When to seek urgent help

• You have a fever of 38°C (100.4°F) or higher, shaking chills or feel suddenly very unwell.
• Jaundice worsens, urine becomes much darker, or a drainage bag suddenly stops filling.
• Pain rapidly worsens, vomiting prevents fluids, or you become confused, dizzy or faint.
• A stent or external drain moves, leaks, blocks, falls out, or the skin around it becomes red or painful.

Treatment may include

Blood tests and cultures, intravenous fluids, antibiotics and urgent restoration of bile flow with an endoscopic stent or an image-guided drain. Cancer treatment may pause until the infection and liver function improve.

Before leaving hospital, confirm

• What stent or drain was placed, where it sits and when it should be reviewed
• Which symptoms require a same-day call and which number works after hours
• When blood tests, antibiotics or the next oncology appointment are due

Tests and diagnosis

Your care team

This is a rare and technically complex cancer. Decisions are safest when specialists review the scans, pathology, liver function and treatment goals together.

A second opinion is particularly valuable before a major resection, transplant pathway, or a final conclusion that surgery is not possible.

How cancer is diagnosed

No single test answers every question. The sequence may change if jaundice or infection needs treatment first.

1. 1

   Confirm the clinical problem with history, examination, liver tests and an initial ultrasound or scan.

2. 2

   Map the tumour with CT scans taken at different times after contrast dye, and/or MRI with detailed bile duct images (MRCP). Scan the chest and other areas where the cancer might have spread.

3. 3

   Decide whether bile drainage is needed and which ducts should be drained before any procedure.

4. 4

   Obtain tissue when it will change management. The safest method depends on tumour site and whether surgery or transplant is planned.

5. 5

   Review pathology, stage and resectability at a multidisciplinary meeting.

6. 6

   If the cancer cannot be removed by surgery or has spread to distant parts of the body (metastatic cancer), arrange broad molecular testing early enough to help guide later treatment.

Tests often happen in parallel

Scans and staging tests

Imaging should define the cancer site, vessels and ducts involved, spread to nodes or organs, and whether enough healthy liver will remain after surgery.

Biopsy and your pathology report

Pathology confirms what the tumour is. It should be reviewed by someone familiar with hepatobiliary cancers, especially when the site of origin is uncertain.

How tissue may be obtained

• From a gallbladder or bile-duct operation
• Brushings or forceps biopsy during ERCP or percutaneous cholangiography
• Endoscopic-ultrasound-guided biopsy of a mass or suspicious lymph node
• Image-guided core biopsy of an intrahepatic mass or metastatic site

What the report should clarify

Molecular testing: finding possible treatment targets

Cancers starting in the same place can have different gene or protein changes, called biomarkers. These can help doctors choose a treatment. Testing is most important when cancer cannot be removed by surgery, has returned (recurrent cancer) or has spread to distant parts of the body.

Ask for a broad panel

Next-generation sequencing (NGS) can test many genes at once. Testing RNA, a molecule that carries genetic instructions, can help detect gene fusions: changes that join parts of different genes together. Some of these changes can be targeted by medicines.

A blood-based ‘liquid biopsy’ can help when tissue is scarce, but a negative blood test may need tissue confirmation.

Planning your treatment

Understanding your stage

Site-specific TNM staging for biliary cancers

Gallbladder, intrahepatic, perihilar and distal bile duct cancers have separate staging rules. Find the starting site first, then read the matching group. In the descriptions below, stages 1–3 have no spread to distant parts of the body. Stage 4 is not always distant spread.

Lymph nodes are small immune-system structures. Regional nodes are those near or draining the cancer’s starting area; distant spread means cancer has reached a site outside that regional area. Stages describe findings, not a sequence that everyone will pass through.

Gallbladder cancer

Depth of growth and nodes matter more than size alone.

Gallbladder cancer: local tumour growth (T)

These illustrations explain the T part of TNM for gallbladder cancer. T1–T4 are not the same as overall stages I–IV: lymph nodes (N) and distant spread (M) also determine the stage. Bile duct cancers use different rules.

T1a and T1b

Growth into the supporting tissue beneath the lining (T1a) or the muscle layer (T1b).

T2

Growth beyond the muscle into surrounding connective tissue. T2a is on the side facing the abdominal cavity; T2b is on the liver side, without growing into the liver.

T3

Growth through the outer surface, into the liver or into one nearby organ. This example shows growth towards the liver.

T4

Growth into a main blood vessel supplying the liver, as shown here, or into two or more nearby organs outside the liver.

Stage 1 (I)

Cancer reaches the supporting layer or muscle of the gallbladder wall, with no cancer found in nearby lymph nodes.

Stage 2 (II)

Cancer reaches tissue around the muscle but not through the outer surface or into the liver. No cancer is found in nearby lymph nodes.

Stage 3 (III)

Cancer grows through the surface, into liver or one nearby organ, or involves 1–3 regional nodes, without stage 4 local features.

Stage 4 (IV)

Growth into major blood vessels or several nearby organs can be stage IVA. Cancer in four or more regional lymph nodes, or spread to distant parts of the body, is stage IVB.

Intrahepatic bile duct cancer: inside the liver

Separate liver tumours and blood-vessel involvement affect the stage.

Stage 1 (I)

One tumour, without growth into blood vessels or cancer in nearby lymph nodes.

Stage 2 (II)

Growth into blood vessels within the liver or more than one tumour, without cancer in nearby lymph nodes.

Stage 3 (III)

Growth through the liver covering, into nearby structures outside the liver, or into regional lymph nodes.

Stage 4 (IV)

Cancer has spread to distant parts of the body.

Perihilar bile duct cancer: at the liver’s hilum

The hilum is where the right and left liver ducts join.

Stage 1 (I)

Cancer stays within the duct wall, with no cancer in regional lymph nodes.

Stage 2 (II)

Growth beyond the duct into surrounding fat or liver, without cancer in regional lymph nodes.

Stage 3 (III)

Growth into particular nearby blood vessels or ducts, or cancer in 1–3 regional lymph nodes. Your team can explain which finding determines your stage.

Stage 4 (IV)

Stage IVA means cancer in at least 4 regional lymph nodes. Stage IVB means spread to distant parts of the body.

Distal bile duct cancer: nearer the bowel

Depth is measured under the microscope, not from the tumour’s overall width.

Stage 1 (I)

Growth less than 5 mm deep into the duct wall, with no cancer in regional lymph nodes.

Stage 2 (II)

Deeper growth or cancer in 1–3 regional lymph nodes, without growth into the major arteries that define stage 3.

Stage 3 (III)

Cancer in at least 4 regional lymph nodes, or growth into particular major arteries.

Stage 4 (IV)

Cancer has spread to distant parts of the body.

Stage 0, when used, means non-invasive abnormal cells in the lining. Whether surgery can remove the cancer safely (resectability) is a separate decision involving bile ducts, major vessels, the amount of healthy liver that would remain and your fitness. A small tumour can still sit in a difficult position.

Clinical stage comes from examination, biopsies and scans. Pathological stage can add information from surgery; a prefix such as yp means the tissue was assessed after treatment. A revised assessment does not necessarily mean the cancer grew while you were waiting. Grade describes the cells’ behaviour and is different from stage.

Incidental gallbladder cancer

Sometimes cancer is found only after the gallbladder has been removed for stones or inflammation. The specialist team should promptly review the operation record, tissue slides, cut edges and new scans. If the cancer reached the muscle layer (T1b) or deeper, a second operation may be recommended when there is no spread and complete removal is possible.

Resectability can change

• A tumour considered unsuitable for surgery at one centre may be operable at a specialist liver and bile duct centre that performs these operations regularly.
• Drainage, nutrition and infection control may make liver surgery safer. In selected cases, a procedure called portal-vein embolisation helps the part of the liver that will remain grow before surgery.
• Systemic or local treatment can occasionally shrink disease enough for reconsideration, but this is not guaranteed.
• New distant spread or inadequate future liver function can make surgery unsafe even when the primary tumour is technically removable.

You can also ask whether the team plans to review the possibility of surgery again after treatment.

Your treatment options at a glance

Treatment planning starts with whether all the cancer can be removed safely. Test results, your overall health and your preferences help guide the next steps.

↓

↓

Treatment goals

Treatment options

Surgery offers the main chance of cure

The operation depends on where the cancer started. The aim is to remove it completely, with no cancer seen at the cut edges under a microscope (an R0 resection), while preserving enough healthy liver and digestive function.

Before committing to a major operation

• Complete staging of the chest, abdomen and pelvis, with MRI/MRCP when duct anatomy needs definition
• Review of the main blood vessels supplying the liver (the portal vein and hepatic artery) and the liver tissue that would remain after surgery
• Assessment of liver function, kidney function, nutrition, heart/lung fitness and frailty
• A drainage plan for selected jaundiced patients—not automatic drainage of every blocked duct
• Possible staging laparoscopy to look for small deposits that imaging can miss
• A clear discussion of expected benefit, complications, hospital stay and recovery

Margin and nodes matter

The surgeon usually removes the tumour with a rim of normal tissue and regional lymph nodes. The final pathology determines stage, prognosis and whether additional treatment is advised.

Gallbladder cancer surgery

The operation depends on how deeply the cancer has grown into the gallbladder wall and whether the first gallbladder removal (cholecystectomy) was done for known cancer or suspected gallstones.

What may be removed

• Gallbladder and the liver tissue directly beneath it
• Lymph nodes along the bile duct and hepatic vessels
• The extrahepatic bile duct if the cystic-duct margin or tumour location requires it
• Occasionally an adjacent organ or vascular segment when an R0 resection remains realistic

Intrahepatic cholangiocarcinoma surgery

This operation removes the liver tumour, an adequate margin and regional lymph nodes while leaving a future liver remnant large and healthy enough to function.

Possible operations

What influences resectability

• Number and distribution of tumours, vascular invasion and regional nodes
• Underlying cirrhosis, fatty liver or cholangitis and the predicted future liver volume
• Whether disease outside the planned resection can be cleared
• The patient’s overall fitness and ability to recover from major liver surgery

Perihilar and distal bile duct surgery

These tumours are close to the liver hilum or pancreas, so their operations differ substantially.

Preparing the liver for perihilar surgery

• Drain the future liver remnant selectively when jaundice, cholangitis or the operation plan makes this necessary.
• Treat infection and improve nutrition before major resection.
• Use portal-vein embolisation in selected patients when the future liver remnant is too small.

A transplant pathway for selected perihilar cancer

Some people with early, unresectable perihilar cholangiocarcinoma may be considered for a strict protocol involving chemoradiation, staging and liver transplant at a specialist centre. Eligibility is narrow.

The biopsy route and previous operations may affect candidacy, so referral should occur before a needle biopsy through the abdominal lining when transplant is a possibility.

Before a transplant-centre referral

• Do not assume every tissue-sampling route is equivalent; ask the specialist centre first.
• Gather a CD containing the original scan images (DICOM format) with viewing software, the written scan reports, drainage records, pathology and complete procedure notes.
• Clarify whether infection control and biliary drainage are adequate for assessment.

Recovery after surgery

Recovery depends on the operation. Cholecystectomy is very different from a major liver resection or Whipple procedure.

Call the surgical team for

• Fever, chills, increasing jaundice, worsening abdominal pain or repeated vomiting
• Redness, pus, opening of a wound, or a sudden change in drain output
• Breathlessness, chest pain, one-sided leg swelling, fainting or confusion
• Inability to eat or drink, persistent diarrhoea, pale greasy stools or rapid weight loss

Before discharge, know

• Which drains, wounds or medicines need daily attention and who will remove them
• The nutrition, enzyme, diabetes and activity plan for the first weeks at home
• The emergency number and the date for pathology and oncology review

Treatment after surgery

Even when surgery removes all visible cancer and the cut edges are clear, tiny groups of cells may remain elsewhere. Treatment after surgery, called adjuvant treatment, aims to reduce the chance of cancer returning; it does not mean cancer is known to remain.

Capecitabine after surgery

For many resected gallbladder and bile-duct cancers, about six months of oral capecitabine is the preferred adjuvant therapy, based largely on the BILCAP study and international guidelines. The decision considers recovery, stage, nodes, margins, liver function and patient preference.

Capecitabine practical points

• Tablets are taken in cycles; the dose is adjusted for kidney function and tolerance.
• Report diarrhoea, mouth ulcers, fever, chest pain and painful redness or peeling of hands/feet early.
• Do not change or stop the dose without contacting the oncology team.

When the cancer cannot be removed now

Cancer may be unresectable because of its location or spread, how much healthy liver would remain, or your overall health. Ask whether treatment aims to shrink it enough to reconsider surgery, control it for longer or relieve symptoms.

Address problems that could delay treatment

• Drain a clinically important obstruction and treat cholangitis
• Treat dehydration, kidney problems and imbalances in blood salts (electrolytes)
• Address pain, itching, nausea, weight loss and poor intake
• Obtain adequate tissue and molecular testing

Treatment routes

First treatment: chemotherapy with immunotherapy

For many adults with untreated, unresectable or metastatic biliary tract cancer, a preferred treatment is gemcitabine plus cisplatin chemotherapy with either durvalumab or pembrolizumab immunotherapy.

What a typical schedule looks like

Gemcitabine and cisplatin are commonly given on days 1 and 8 of a 21-day cycle, with the immunotherapy on day 1. Cisplatin is usually limited to an initial course; immunotherapy may continue as maintenance treatment to help keep the cancer under control.

Exact doses, cycle count and maintenance duration follow the chosen protocol and the patient’s tolerance.

Choosing and adapting treatment

• No trial directly comparing durvalumab with pembrolizumab has established that one is better.
• Kidney function, hearing, nerve symptoms such as numbness or tingling (neuropathy), infection, bilirubin levels and how well you manage daily activities may affect treatment timing, dose or choice of chemotherapy.
• Some frail patients benefit more from gentler chemotherapy or symptom-focused care than from a three-drug regimen.

When treatment needs to change

Treatment may change because scans show growth, side effects outweigh benefit, infection or liver dysfunction intervenes, or a biomarker result creates a better option.

Second-line and later treatment

How the next choice is made

• Previous benefit and toxicity, neuropathy, blood counts, kidney/liver function and current fitness
• Cancer pace and location, symptoms, stent reliability and need for rapid shrinkage
• Molecular results, medicine access, cost and the patient’s priorities

Targeted medicines: FGFR2, IDH1 and BRAF

These changes are found mainly in bile duct cancers inside the liver. Treatment needs a reliable laboratory result and careful monitoring for side effects.

FGFR treatment practical points

• FGFR2 fusions are different from isolated FGFR changes of uncertain significance; the exact report matters.
• Phosphate, a mineral in the blood, can rise during treatment. This may need dietary advice, medicines that reduce phosphate absorption or a dose adjustment.
• Blurred vision, flashes or new floaters need prompt eye review.
• Resistance can emerge; a clinical trial or repeat molecular test may sometimes clarify a new option.

Targeted medicines: HER2 and rare gene changes

Some biliary cancers make unusually large amounts of HER2 protein or have a rare gene fusion. These findings may guide treatment. You do not need every medicine listed below: your oncologist will explain which, if any, matches your test results and previous treatment.

HER2 safety differs by drug

HER2 antibodies can cause infusion reactions and reduced heart function. Trastuzumab deruxtecan can cause serious lung inflammation (interstitial lung disease); new cough or breathlessness needs urgent assessment. Zanidatamab commonly causes diarrhoea and infusion reactions and can harm an unborn baby.

Radiotherapy and liver-directed treatment

Local treatment can complement systemic therapy when disease is confined, liver-dominant, threatening a structure or causing symptoms.

Planning protects normal tissue

• Previous operations, stents and infections affect radiation and embolisation risk.
• The liver, stomach, duodenum, bowel, kidneys and spinal cord have dose limits.
• Combining local and systemic therapy requires a deliberate sequence and recovery plan.

Managing side effects

During chemo-immunotherapy

Side effects vary. Reporting symptoms early helps the team offer medicines, adjust doses and treat inflammation caused by immunotherapy before it becomes severe.

Before each cycle

• Blood count, kidney/liver function and electrolytes; thyroid tests at intervals
• Review of fever, jaundice, stent/drain function, new breathlessness, diarrhoea, rash or unusual fatigue
• Hydration and anti-sickness plan; hearing assessment when clinically indicated
• Dose and timing adjusted to recovery—not simply to the calendar

Biliary drainage and stents

Drainage can relieve jaundice, treat or prevent infection, improve liver function and make surgery or systemic treatment safer—but it also carries risks.

Live well

Supportive care and nutrition

Supportive and palliative care helps with symptoms, emotional wellbeing and practical needs. It can be provided alongside cancer treatment at any stage.

Eating with biliary cancer

• Do not adopt a severe low-fat or ‘anti-cancer’ diet without advice; unnecessary restriction can worsen weight loss.
• Aim for frequent energy- and protein-rich meals, enough fluid and safe food handling during low blood counts.
• Tell the team about herbal or Ayurvedic products because some can injure the liver or interact with treatment.

Follow-up after treatment

Follow-up checks for signs that cancer has returned, manages lasting treatment effects, monitors stents and supports recovery. Your team will agree a schedule with you. Report new symptoms between visits rather than waiting for the next appointment.

After curative-intent treatment

A common approach is clinical review, imaging and tumour markers such as CA 19-9 and CEA every 3–6 months for the first 2 years, then every 6–12 months up to 5 years, adjusted for site, stage, treatment and symptoms.

CA 19-9 is most useful when it was high before treatment. Jaundice or infection can also raise it, so your team interprets the result alongside symptoms and scans.

Related care

Explore treatments

Medical Oncology↗Ports, PICCs, and venous access↗Stem Cell Transplant & Cellular Therapy↗Cancer Surgery↗Radiation Oncology↗Cancer Diagnostics & Molecular Testing↗Supportive & Holistic Cancer Care↗

Meet our doctors

Dr (Prof) Vijay Agarwal

Professor and Lead Consultant – Medical Oncology

Dr Prathyush V

Senior Consultant – Medical Oncology & Haemato-Oncology

Dr Darshan R S

Consultant – Medical Oncology & Haemato-Oncology

Where to get care

Bannerghatta Road

Apollo Hospitals
Bengaluru

Seshadripuram

Apollo Hospitals
Bengaluru

Sarjapur

Apollo Hospitals
Bengaluru

Jayanagar

Apollo Speciality Hospital
Bengaluru